Note: Descriptions are shown in the official language in which they were submitted.
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 1 -
NANOEMULSIONS WITH COLOR STABILIZED ACTIVES
Field of the invention
The present invention is directed to nanoemulsions that stabilize actives like
retinoic
acid precursors. More particularly, the invention is directed to nanoemulsions
that are
preferably water continuous and suitable to be dispersed in end use skin
benefit
compositions. The nanoemulsions comprise at least 30% by weight oil, and
surprisingly, improve color stability of actives present therein.
Background of the invention
Many consumers find it desirable to deliver skin benefits via methods that
rely on the
application of topical compositions. This is especially true when consumers
wish to
look younger by reducing facial lines and wrinkles as well as blotchy color
marks on the
skin.
Minimizing cutaneous aging, both intrinsic and from photoaging, is often
attempted with
compositions having, for example, actives such as retinoic acid precursors,
resorcinols
and the like. While such compositions can provide benefits to skin,
instability of such
actives typically results in formulation discoloration leading to consumer
dissatisfaction
with such compositions. This is true because a product that discolors often
results in a
consumer discarding the product for fear that the same is no longer
efficacious.
It is of increasing interest to develop a stable skin benefit composition with
active where
the same is suitable to provide benefits to skin and has reduced amounts of
premature
discoloration originating from the active present therein.
This invention, therefore, is directed to a skin benefit composition with
stabilized actives
like resorcinol and retinoic acid precursors. The composition of the present
invention
surprisingly can be topically applied without causing skin irritation and
displays reduced
discoloration while simultaneously delivering excellent skin benefits. The
present
invention includes a nanoemulsion with active that is suitable to be dispersed
in a
chassis to yield an end use skin benefit composition. The nanoemulsion
comprises at
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 2 -
least 30% by weight oil, and surprisingly, improves color stability of end use
compositions they are formulated in by preventing degradation of active
resulting from
active exposure to heat, oxygen, ultraviolet light or the like.
Additional Information
Efforts have been disclosed for making formulations to treat skin. In U.S.
Patent No.
4,826,828, retinol comprising compositions with volatile silicones are
described.
Still other efforts have been disclosed for making formulations to treat skin.
In U.S.
Patent Application No. 2010/0305218, oil-in-water nanoemulsions suitable as
active
delivery vehicles are described.
Even other efforts have been disclosed for making formulations to treat skin.
In
BRP10905347, deformable nanocapsules are described.
U.S. Patent Nos. 6,863,897, 6,869,598, and 6,858,217 all describe topical
compositions with resorcinols. In Korean Patent KR10100243361, nanoemulsions
with
actives are described.
None of the additional information above describes a composition with
stabilized
actives as claimed in this invention.
Summary of the invention
In a first aspect, the present invention is directed to a nanoemulsion
comprising:
(a) active;
(b) water;
(c) water soluble humectant;
(d) oil, and
(e) emulsifier
wherein the active is soluble in the oil, the nanoemulsion has a particle size
from 0.05
microns to less than 1.5 microns and comprises at least 30% by weight oil.
CA 03069484 2020-01-09
WO 2019/011618
PCT/EP2018/066640
- 3 -
In a second aspect, the invention is directed to an end use skin benefit
composition
comprising dispersed therein at least 25% by weight of the nanoemulsion of the
first
aspect of this invention.
In a third aspect, the invention is directed to a method for preventing
composition
discoloration by preparing an end use skin benefit composition with active in
the
nanoemulsion as described in the first aspect of the invention.
All other aspects of the present invention will readily become apparent upon
considering the detailed description and examples which follow.
Skin, as used herein, is meant to include skin on the feet, face, neck, chest,
back,
arms, under arms, hands, legs, buttocks and scalp (including hair). The end
use skin
benefit composition of this invention includes creams, lotions, balms, serums,
deodorants and antiperspirants, shampoos, conditioners, bars and liquid wash
products. In a preferred embodiment, the end use composition of this invention
is a
leave-on composition like a leave-on cream or lotion, and especially, one to
be applied
to the face and/or hands.
Active, as used herein, means an oil soluble agent that benefits skin (like a
resorcinol
derivative or the like) or a precursor to an agent that benefits skin like
retinoic acid
precursors. Active, therefore, is an agent that is suitable to be formulated
in the oil
phase of the nanoemulsion described in this invention to improve a skin
characteristic.
Retinoic acid precursor means a component that, when oxidized, can convert to
retinoic acid (especially after penetrating the skin). Examples of such a
component
include retinol, retinal, retinyl propionate, retinyl palmitate, retinyl
acetate,
hydroxyanasatil retinoate (i.e., Retextra ) mixtures thereof or the like.
Unless explicitly
stated otherwise, all ranges described herein are meant to include all ranges
subsumed therein. The term comprises is meant to encompass the terms
consisting
essentially of and consisting of. For the avoidance of doubt, and for example,
a
composition comprising retinoic acid precursor and resorcinol is also meant to
include
a composition consisting essentially of and a composition consisting of the
same. All
percentages used herein are meant to be by weight unless stated otherwise. End
use
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 4 -
skin benefit composition means a composition ready for application (e.g.,
topically) by a
consumer. The end use skin benefit composition of the invention, which is
suitable to
provide benefit to skin, carries in dispersed form the nanoemulsions described
in this
invention whereby the same may be interchangeably used with end use
composition.
The end use composition may have emulsion or structured water as a chassis to
carry
the nanoemulsion. The end use composition can be oil or water continuous, but
a
water continuous chassis and end use composition are preferred. Color
stability
means no visible change in color after spending 8 weeks at 45 C, and
particularly, a
AE of 10% or less (i.e., less color change) measured against macroemulsion of
the
.. same composition after assessing both compositions at, again, 45 C after 8
weeks with
a Hunter L,a,b Colorimeter. Resorcinol derivative means at least one hydrogen
on the
ring structure and/or on the hydroxy group of the resorcinol is/are replaced
with, for
example, an alkyl group. Nanoemulsion, as used herein, means an emulsion
having a
particle size of 0.05 to less than 1.5 microns. Nanoemulsion also means the
emulsion
added to and dispersed in an emulsion or structured water to yield end use
skin benefit
composition. Macroemulsion means having a particle size of 1.5 microns or
greater.
Particle size, as used herein, means the largest measurable diameter (based on
volume average of a non-perfect sphere) of the nanoemulsion particle.
Structured
water is defined to mean water with at least 0.2% by weight thickening agent
and
.. having a viscosity from 1,500 to 100,000 cps. Viscosity as noted herein is
taken on a
Brookfield Viscometer (DV-1+), sample temperature at 25 degrees celsius,
20RPM,
RVG, 30 seconds.
Except in the operating and comparative examples, or where otherwise
explicitly
indicated, all numbers in this description indicating amounts or ratios of
materials or
conditions and/or physical properties of materials and/or use thereof are to
be
understood as modified by the word "about".
Detailed description of the invention
The only limitation with respect to the active suitable for use in this
invention is that the
same is soluble in the oil within the internal phase of the nanoemulsion.
Preferred
actives suitable for use are retinoic acid precursors. Illustrative examples
of the
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 5 -
retinoic acid precursors that may be used in this invention include those
represented by
the formula
X
where each R is independently a hydrogen or a 01-6 alkyl group and X is
0 0
5 ¨OH, ¨CH, or¨O¨C __ (C(R1)2)nC(R1)3
and further where each R' is hydrogen or a 01-03 alkyl and n is an integer
from 0 to 16
(preferably, 1 to 5).
Preferably, the retinoic acid precursor is retinol, retinal, retinyl
propionate, retinyl
palmitate, retinyl acetate or a mixture thereof. Retinyl palmitate (n=14),
R=0H3, R'=H,
X= ¨ 0 C(CH2)CH3 (n=14 and R'=1-1)
is a preferred retinoic acid precursor. Retinyl propionate is most preferred,
Ti
R=CH3 X= -0-C-(C1-12)10H3 (n=1 and IT=E1).
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 6 -
Still another retinoic acid precursor suitable for use is hydroxyanasatil
retinoate made
commercially available under the name Retextra as supplied by Molecular
Design
International. The same may be used in a mixture with the precursors described
herein.
Other preferred actives suitable for use include resorcinol (benzenediol) and
its
derivatives like 4-ethyl resorcinol, 4-hexyl resorcinol, 4-phenylethyl
resorcinol, 4-
cyclopentyl resorcinol, 4-cyclohexyl resorcinol, 4-isopropyl resorcinol
mixtures thereof
or the like. Additional resorcinol derivatives suitable for use are 5-
substituted resorcinol
derivatives as described in commonly assigned U.S. Published Patent
Application No.
2016/0000669A1. These additional resorcinols are represented by the formula
OH
=
OH
R"
where R" and R" are each independently an alkyl, alkenyl, aryl or halogen.
Preferred
5-substituted resorcinols include 4-cyclohexy1-5-methylbenzene-1,3-diol, 4-
isopropyl-5-
methylbenzene-1,3-diol, mixtures thereof or the like.
Typically the amount of active used in the nanoemulsions of this invention is
from 0.001
to 10%, and preferably, from 0.01 to 6%, and most preferably, from 0.05 to
3.5%,
based on total weight of the nanoemulsion and including all ranges subsumed
therein.
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 7 -
Water typically makes up from 10% to less than 70%, and preferably, from 12%
to
65%, and most preferably, from 19 to 55% by weight of the nanoemulsion,
including all
ranges subsumed therein. In a preferred embodiment, the nanoemulsion has a
particle
size from 0.1 to 0.8 microns, and preferably, from 0.1 to 0.6 microns. In a
most
preferred embodiment, the nanoemulsion described in this invention is water
continuous.
The humectant suitable for use in the nanoemulsions of this invention is one
which is
water soluble and forms part of the phase with water present. Illustrative
examples of
the humectants suitable for use in the nanoemulsions include glycerine,
glycerol,
sorbitol, polyethylene glycol, dipropylene glycol, polypropylene glycol,
hydroxypropyl
sorbitol, hexylene glycol, 1,3-butylene glycol, isoprene glycol, mixtures
there or the like.
Typically, the humectants suitable for use in the nanoemulsion of this
invention make
up from about 0.5 to 50%, and preferably, from 1 to 40%, and most preferably,
from 1
to 35% by weight of the nanoemulsion, including all ranges subsumed therein.
Such
humectants may be used in the chassis that forms part of the end use skin
benefit
compositions but usually at half the amounts noted for use in the
nanoemulsions.
The nanoemulsions of this invention will have cosmetically acceptable
carriers, like oils,
for oil soluble active to be dissolved therein. Such oils may also be used in
forming the
continuous or internal phase of the chassis used in combination with
nanoemulsion for
making the end use skin benefit composition when such chassis for the
nanoemulsion
is not structured water.
As to the chassis of the end use skin benefit compositions, water is the most
preferred
carrier. Amounts of water may range from 1 to less than 75%, and preferably,
from 5 to
less than 70%, and most preferably, from 35 to 65%, and optimally, from 40 to
65% by
weight, based on total weight of the chassis of the end use skin benefit
composition
and including all ranges subsumed therein. Ordinarily the end use compositions
of this
invention will be water and oil emulsions, most preferably, of the oil-in-
water variety.
Water-in-oil emulsions, and especially, those generally classified as water-in-
oil and
high internal phase emulsions are, however, an option. Illustrative examples
of the high
internal phase emulsions suitable to act as a chassis for the nanoemulsions of
this
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 8 -
invention are described in commonly owned U.S. Patent Application Publication
No.
2008/0311058 and U.S. Patent No. 8,425,882.
Mineral oils, silicone oils, esters, and alcohols can be used in the
nanoemulsion and
chassis of the end use skin benefit composition described herein. Amounts of
these
materials may collectively range from 0.1 to less than 75%, and preferably,
from 0.1 to
45%, and most preferably, from 1 to 20% by weight of the chassis of the end
use skin
benefit composition of this invention, including all ranges subsumed therein.
As to the
nanoemulsion, typically the same comprises at least 30% by weight oil, and
preferably,
from 30 to 65%, and most preferably, from 36 to 60% by weight oil, based on
total
weight of the nanoemulsion and including all ranges subsumed therein.
Silicone oils, suitable for use in the nanoemulsions and the chassis of the
end use skin
benefit compositions of this invention, may be divided into the volatile and
non-volatile
variety. The term "volatile" as used herein refers to those materials which
have a
measurable vapor pressure at ambient temperature. Volatile silicone oils are
preferably
chosen from cyclic or linear polydimethylsiloxanes containing from 3 to 9, and
preferably, from 4 to 5 silicon atoms.
Linear volatile silicone materials generally have viscosities of less than 5
centistokes at
C. while cyclic materials typically have viscosities of less than about 10
centistokes.
Nonvolatile silicone oils useful as carrier material include polyalkyl
siloxanes,
polyalkylaryl siloxanes and polyether siloxane copolymers. The essentially non-
volatile
25 polyalkyl siloxanes useful herein include, for example,
polydimethylsiloxanes (like
dimethicone) with viscosities of from 5 to 100,000 centipoise at 25 C.
An often preferred silicone source is a cyclopentasiloxane and dimethiconol
solution.
Among suitable esters are:
(I) Alkenyl or alkyl esters of fatty acids having 10 to 20 carbon atoms like
isopropyl palmitate, isopropyl isostearate, isononyl isonanonoate, leyl
myristate,
isopropyl myristate, ()leyl stearate, and ()ley! oleate;
(2) Ether-esters such as fatty acid esters of ethoxylated fatty alcohols;
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 9 -
(3) Polyhydric alcohol esters such as ethylene glycol mono- and di-fatty acid
esters, diethylene glycol mono- and di-fatty acid esters, polyethylene glycol
(200-6000)
mono- and di-fatty acid esters, propylene glycol mono- and di-fatty acid
esters,
polypropylene glycol 2000 monooleate, polypropylene glycol 2000 mono stearate,
.. ethoxylated propylene glycol monostearate, glyceryl mono- and di-fatty acid
esters,
polyglycerol poly-fatty esters, ethoxylated glyceryl mono-stearate, 1,3-
butylene glycol
monostearate, 1,3-butylene glycol distearate, polyoxyethylene polyol fatty
acid ester,
sorbitan fatty acid esters, and polyoxy-ethylene sorbitan fatty acid esters;
(4) Wax esters such as beeswax, spermaceti, myristyl myristate, stearyl
stearate; and
(5) Sterol esters, of which soya sterol and cholesterol fatty acid esters are
examples thereof.
Often, oils such as caprylic capric triglyceride are preferred as carriers.
Emulsifiers suitable for use in the nanoemulsions and the chassis used to
yield the end
use skin benefit compositions of the present invention (when the chassis is
not
structured water) will have an HLB from 4-17. The HLB of the emulsifier used
will be 4-
6 when oil continuous emulsions and nanoemulsions are desired. Preferably the
emulsions have an HLB from 7 to 17, and preferably, from 7 to 16, and most
preferably, 8 to 14, including all ranges subsumed therein. Total
concentration of the
emulsifier (in the chassis used for end use composition) may range from about
0.1 to
40%, and preferably, from 1 to 20%, and most preferably, from 1 to 5% by
weight of the
composition, including all ranges subsumed therein. Total amount of emulsifier
used
within the nanoemulsion is typically from 5 to 18%, and preferably, from 6 to
15%, and
most preferably, from 7 to 11% by weight, including all ranges subsumed
therein. The
emulsifier may be selected from the group consisting of anionic, nonionic,
cationic and
amphoteric actives. Particularly preferred nonionics are those with a 010-020
fatty
alcohol or acid hydrophobe condensed with from about 2 to about 100 moles of
.. ethylene oxide or propylene oxide per mole of hydrophobe; 02-010 alkyl
phenols
condensed with from 2 to 20 moles of alkylene oxide; mono- and di-fatty acid
esters of
ethylene glycol; fatty acid monoglyceride; sorbitan, mono- and di-08-020 fatty
acids; and
polyoxyethylene sorbitan as well as combinations thereof. Alkyl polyglycosides
and
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 1 0 -
saccharide fatty amides (e.g. methyl gluconamides) are also suitable nonionic
emulsifiers.
Preferred anionic emulsifiers include alkyl ether sulfate and sulfonates,
alkyl sulfates
and sulfonates, alkylbenzene sulfonates, alkyl and dialkyl sulfosuccinates, 08-
020
acyl isethionates, 08-020 alkyl ether phosphates, alkyl ether carboxylates and
combinations thereof.
Cationic emulsifiers that may be used include, for example,
palmitamidopropyltrimonium chloride, distearyldimonium chloride and mixtures
thereof.
Useful amphoteric emulsifiers include cocoamidopropyl betaine, 012-020
trialkyl
betaines, sodium lauroamphoacetate, and sodium laurodiamphoacetate or a
mixture
thereof.
The generally preferred emulsifiers include glyceryl stearate, glycol
stearate,
stearamide AMP, PEG-100 stearate, cetyl alcohol as well as
emulsifying/thickening
additives like hydroxyethylacrylate/sodium acryloyldi methyl taurates
copolymer/squalane and mixtures thereof.
In an especially preferred emobodiment, the emulsifier used in the
nanoemulsion is
Tween 40 (polyoxyethylene sorbitan monopalmitate). In another especially
preferred
embodiment, the nanoemulsions of this invention are used to prevent end use
composition discoloration originating from actives.
Preservatives can desirably be incorporated into the nanoemulsions and the
chassis of
the end use skin benefit compositions of this invention to protect against the
growth of
potentially harmful microorganisms. Suitable traditional preservatives for
compositions
of this invention are alkyl esters of para-hydroxybenzoic acid. Other
preservatives
which have more recently come into use include hydantoin derivatives,
propionate
salts, and a variety of quaternary ammonium compounds. Cosmetic chemists are
familiar with appropriate preservatives and routinely choose them to satisfy
the
preservative challenge test and to provide product stability. Particularly
preferred
preservatives are iodopropynyl butyl carbamate, phenoxyethanol,
hydoxyacetophenore, 1,2-octanediol, ethylhexylglycerine, hexylene glycol,
methyl
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 11 -
paraben, propyl paraben, imidazolidinyl urea, sodium dehydroacetate and benzyl
alcohol. The preservatives should be selected having regard for the use of the
composition and possible incompatibilities between the preservatives and other
ingredients in the emulsion. Whether nanoemulsion or the chassis of the end
use skin
benefit composition, preservatives are preferably employed in amounts ranging
from
0.01% to 2% by weight of the total weight of the nanoemulsion and end use skin
benefit composition, including all ranges subsumed therein. Combinations of
1,2-
octanediol and phenoxyethanol, or iodopropynyl butyl carbamate and
phenoxyethaol
are preferred, with phenoxyethanol making up from 35 to 65% by weight of the
total
weight of the preservative combination with the phenoxyethanol.
Thickening agents may optionally be included in the nanoemulsions and the
chassis of
the end use skin benefit compositions of the present invention. Particularly
useful are
the polysaccharides. Examples include starches, natural/synthetic gums and
cellulosics. Representative of the starches are chemically modified starches
such as
sodium hydroxypropyl starch phosphate and aluminum starch octenylsuccinate.
Tapioca starch is often preferred. Suitable gums include xanthan, sclerotium,
pectin,
karaya, arabic, agar, guar, carrageenan, alginate and combinations thereof.
Suitable
cellulosics include hydroxypropyl cellulose, hydroxypropyl methylcellulose,
ethylcellulose and sodium carboxy methylcellulose. Synthetic polymers are yet
another
class of effective thickening agent. This category includes crosslinked
polyacrylates
such as the Carbomers, polyacrylamides such as Sepigel 305 and taurate
copolymers
such as Simulgel EG and Arlstoflex AVC, the copolymers being identified by
respective
INCI nomenclature as Sodium Acrylate/Sodium Acryloyldimethyl Taurate and
Acryloyl
Dimethyltaurate/Vinyl Pyrrolidone Copolymer. Another preferred synthetic
polymer
suitable for thickening is an acrylate-based polymer made commercially
available by
Seppic and sold under the name Simulgel INS100.
Amounts of the thickener, when used in the nanoemulsion and the chassis of the
end
use skin benefit composition when an emulsion may range from 0.0 to 5%, and
preferably, from 0.1 to 2%, and most preferably, from 0.2 to 1.0% by weight of
the
nanoemulsion and/or the chassis of the end use composition and including all
ranges
subsumed therein.
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 12 -
When the end use skin benefit composition is nanoemulsion dispersed in
structured
water, the structured water typically comprises from 0.2 to 5%, and
preferably, from 0.4
to 2.5%, and most preferably, from 0.5 to 1.6% by weight thickener, based on
total
weight of the end use skin benefit composition, and including all ranges
subsumed
therein.
When structured water is the chassis, it is typically from 35 to 75%, and
preferably,
from 40 to 70%, and most preferably, from 45 to 65% by weight water, based on
total
weight of the structured water and including all ranges subsumed therein.
Typically, at
least 25% and often from about 30 to 60%, and preferably, 35 to 60%, and most
preferably, 40 to 50% by weight nanoemulsion is added to emulsion chassis or
structured water chassis to yield end use skin benefit composition, based on
total
weight of the end use skin benefit composition and including all ranges
subsumed
therein.
The oil and water phases described herein (whether nanoemulsion or chassis)
may
include additional optional additives (skin benefit agents or actives that
generally do not
contribute to composition discoloration) that are soluble in them.
Illustrative examples
are vitamins like Vitamin B2, Vitamin B3 (niacinamide), Vitamin Bs, Vitamin C,
Vitamin
E, Folic Acid and Biotin. Derivatives of the vitamins may also be employed.
For
instance, Vitamin C derivatives include ascorbyl tetraisopalmitate, magnesium
ascorbyl
phosphate and ascorbyl glycoside. Derivatives of Vitamin E include tocopheryl
acetate,
tocopheryl palmitate and tocopheryl linoleate. DL-panthenol and derivatives
may also
be employed and Vitamin D and K are also options. Total amount of optional
vitamins
when present in either phase may range from 0.0 to 10%, preferably from 0.001
to 1%,
optimally from 0.01 to 0.5% by weight of the nanoemulsion and/or chassis of
the end
use skin benefit composition.
Other optional additives suitable for use in this invention include alpha-
and/or beta-
hydroxyacids, 12-hydroxystearic acid, petroselinic acid, conjugated linoleic
acid,
creatine, creatinine, retinoid boosters (e.g., climbazole, bifonazole,
farnesole,
glycyrrchetinic acid, ursolic acid, geranyl geraniol, leyl betaine, hexanoyl
sphingosine)
mixtures thereof or the like. Such additives, when used, collectively make up
from
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 13 -
about 0.001 to about 12% by weight of the nanoemulsion and/or the chassis of
end use
composition.
Optionally, and in the end use skin benefit composition, desquamation
promoters may
be present. Illustrative are the alpha-hydroxycarboxylic acids, beta-
hydroxycarboxylic
acids. The term "acid" is meant to include not only the free acid but also
salts and Cl-
030 alkyl or aryl esters thereof and lactones generated from removal of water
to form
cyclic or linear lactone structures. Representative acids are glycolic and its
derivatives,
lactic and malic acids. Salicylic acid is representative of the beta-
hydroxycarboxylic
acids. Amounts of these materials when present may range from 0.01 to 15% by
weight of the nanoemulsion and chassis, indvidually.
A variety of herbal extracts may optionally be included in the nanoemulsion
and/or end
use compositions of this invention. The extracts may either be water soluble
or water-
insoluble and thus carried in a solvent which respectively is hydrophilic or
hydrophobic.
Water and ethanol are the preferred extract solvents. Illustrative extracts
include those
from green tea, yarrow, chamomile, licorice, aloe vera, grape seed, citrus
unshui,
willow bark, sage, thyme and rosemary. Typically, and when present, extracts
make up
from about 0.01 to 2% by weight of the nanoemulsion and/or chassis of the end
use
composition.
Also optionally suitable for use include materials like chelators (e.g.,
EDTA), opacifiers
(like TI02, Particle size from 50 to 1200nm, and preferably, 50 to 350nm), 08-
22 fatty
acid substituted saccharides, lipoic acid, retinoxytrimethylsilane (available
from Clariant
Corp. under the SilCare IM-75 trademark), dehydroepiandrosterone (DHEA) and
combinations thereof. Ceramides (including Ceramide I, Ceramide 3, Ceramide 36
and
Ceramide 6) as well as pseudoceramides may also be useful. Amounts of these
materials may range from 0.000001 to 10%, preferably from 0.0001 to 1% by
weight of
the nanoemulsion and/or chassis end use composition of this invention.
Sunscreen actives may also be included in the nanoemulsions and/or chassis of
the
end use compositions of the present invention. Particularly preferred are such
materials
as ethylhexyl p-methoxycinnamate, available as Parsol MCX, Avobenzene,
available
as Parsol 1789 and benzophenone-3, also known as Oxybenzone. Inorganic
CA 03069484 2020-01-09
WO 2019/011618 PCT/EP2018/066640
- 14 -
sunscreen actives may be employed such as microfine titanium dioxide,
octocrylene,
zinc oxide, polyethylene and various other polymers.
Amounts of the sunscreen agents when present may generally range from 0.1 to
30`)/0,preferably from 0.5 to 20%, optimally from 0.75 to 10%by weight of the
nanoemulsion and/or chassis of the end use composition.
Fragrances, fixatives and abrasives may optionally be included in end use skin
benefit
compositions of the present invention. Each of these substances may range from
about
0.05 to about 5%, preferably between 0.1 and 3% by weight of the nanoemulsion
and/or chassis of the end use composition.
Conventional buffers/pH modifiers may be used in the nanoemulsions and/or end
use
compositions of this invention. These include commonly employed additives like
sodium hydroxide, potassium hydroxide, hydrochloric acid, citric acid and
citrate/citric
acid buffers. In an especially preferred embodiment, the pH of the
nanoemulsion and
chassis of the end use composition of this invention is from 4 to 8, and
preferably, from
4.25 to 7.75, and most preferably, from 6 to 7.5, including all ranges
subsumed therein.
The nanoemulsions described in this invention may be prepared by mixing water,
oil,
active, humectant and emulsifier with a commercially available sonicator like
those sold
under the name Q Sonica, Mettler and EpiShearTM. An often preferred technique
includes use of a high pressure homogenizer such as one sold under the name
Nano
DeBEE from BEE international with homogenization pressure set at 1500 to 6000
psi,
and preferably 1750 to 3500 psi, and most preferably from 1850 to 2500 psi,
including
all ranges subsumed therein. Macroemulsions described in this invention may be
made
using standard rotor/stator mixers such as those made commercially available
as a
SiIverson L4R mixer.
When making the end use composition of this invention, the desired ingredients
are
mixed under moderate shear and atmospheric pressure with a commercially
available
homogonizer.
CA 03069484 2020-01-09
WO 2019/011618
PCT/EP2018/066640
- 15 -
The viscosity of the nanoemulsions and end use skin benefit composition is
from 1500
to 100,000 cps, and preferably, from 3000 to 75,000 cps, and most preferably
from
5,000 to 20,000 cps, including all ranges subsumed therein.
A wide variety of packaging can be employed to store and deliver the end use
skin
benefit composition of this invention. Packaging is often dependent upon the
type of
personal care end-use. For instance, leave-on skin lotions and creams,
shampoos,
conditioners and shower gels generally employ plastic containers with an
opening at a
dispensing end covered by a closure. Typical closures are screw-caps,
nonaerosol
pumps and flip-top hinged lids. Packaging for antiperspirants, deodorants and
depilatories may involve a container with a roll-on ball on a dispensing end.
Alternatively these types of personal care products may be delivered in a
composition
formulation in a container with a propel repel mechanism. Metallic cans
pressurized by
a propellant and having a spray nozzle serve as packaging for antiperspirants,
shave
.. creams and other personal care products.
The following examples are provided to facilitate an understanding of the
present
invention. The examples are not intended to limit the scope of the claims.
Examples
Macroemulsions were made by mixing the identified ingredients using a bench
top
SiIverson L4R rotor/stator mixer. The nanoemulsions were made by passing the
resulting macroemulsions through a BEE International Nano DeBEE high pressure
homogonizerwith pressure set at 2000 psi.The resulting emulsions had a
particle size
as indicated. All samples had 0.6% by weight retinyl propionate.
Table I (Emulsions)
Ingredients Sample 1 Sample 2 Sample 3
(weight %) (weight %) (weight
%)
Water Balance Balance Balance
Glycerine 1.4 1.4 31.4
Mineral Oil 44 54 44
CA 03069484 2020-01-09
WO 2019/011618
PCT/EP2018/066640
- 16 -
Emulsifier (HLB 15) 9.9 9.9 9.9
Macroemulsion 8.0 11.0 1.84
(particle size, microns)
Nanoemulsion 0.3 0.65 0.27
(particle size, microns)
Example 2
End use skin care compositions were made by mixing, under moderate shear
(ambient
temperature and atmosphere pressure), the emulsions identified in Example 1
with
structured water chassis as identified below.
CA 03069484 2020-01-09
WO 2019/011618
PCT/EP2018/066640
- 17 -
Table ll (End Use Compositions)
Ingredient weight %
Water Balance
Glycerin 4
EDTA 0.03
Thickener* 0.8
Preservative 0.4
Nanoemulsion or Macroemulsion ** 45
* Ammonium Acryloy/dimethyltaurate/VP copolymer
** Six (6) end use compositions were made with nano- and macroemulsion taken
from
each Sample 1-3 as identified in Table 1 of Example 1.
.. Example 3
Color stability of the end use skin benefit compositions made in Table II was
assessed
at 4 and 8 weeks. Temperature was kept constant at 45 C. The apparatus used to
assess color stability was a Hunter L, a, b Colorimeter.
Table III (AE at 4 and 8 weeks (of End Use Compositions of Table II)
4 weeks 8 weeks
Sample 1 macroemulsion 7.4 11.4
Sample 1 nanoemulsion 4.0 6.5
Sample 2 macroemulsion 4.9 8.0
Sample 2 nanoemulsion 3.0 5.0
Sample 3 macroemulsion 7.8 8.2
Sample 3 nanoemulsion 4.5 7.3
The results above in Table III unexpectedly show that when making an active
comprising nanoemulsion according to this invention, color instability
resulting from the
active is reduced in end use skin benefit compositions.
